Drugs / FOG-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05919264 | May 2023 → Apr 2027 expected | adamantinous craniopharyngioma, castration-resistant prostate carcinoma, classic familial adenomatous polyposis, colorectal cancer +4 | Parabilis Medicines, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FOG-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05919264 ↗ |
| Route | Intravenous | “administered IV” NCT05919264 ↗ |